AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

NZ sharemarket down 0.1% on inflation news
Markets Market Close

NZ sharemarket down 0.1% on inflation news

The S&P/NZX 50 Index closed at 13,019.83, down 15.76 points or 0.12%.

Fonterra urges Canada to 'play by the rules'
Primary Sector

Fonterra urges Canada to 'play by the rules'

NZ, US and Australia believe Canada is undermining legitimate export interests.

Too few NZ ports earning 'appropriate returns'
Infrastructure

Too few NZ ports earning 'appropriate returns'

Port returns over the past decade 'disappointing and alarming'.